Diabetes risk assessment in adult population without diabetes employing continuous glucose monitoring: A novel approach
Loading...
Identifiers
Publication date
Advisors
Tutors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
Aims
Time above range obtained through continuous glucose monitoring (CGM) is a useful marker for identifying individuals at higher risk of developing diabetes. We aimed to determine the optimal cutoff for the percentage of time glucose exceeds a threshold to predict diabetes onset.
Methods
Prospective observational study involving CGM in individuals without diabetes. Individuals who completed CGM and were not diagnosed with diabetes at baseline were followed for a median of 10.8 years.
Results
Among 513 individuals (median age: 46; range: 18–82), 42 developed diabetes during follow-up. Individuals who developed diabetes were older (median age [IQR]: 53 [45–63] vs. 45 [35–57] years; p < 0.001) and had a higher BMI (32.2 [28.9–35.2] vs. 26.8 [23.8–30.3] kg/m2; p < 0.001) compared to those who did not. The most significant differences between those who developed diabetes and those who did not were observed when we set a cutoff of ≥ 130 mg/dL for at least 10 % of monitoring time.
Conclusions
CGM provides highly useful information for predicting type 2 diabetes. In healthy individuals, exhibiting glucose levels at or above 130 mg/dL for over 10 % of the time over at least two monitoring days show a higher risk of developing type 2 diabetes.
Description
Bibliographic citation
Diabetes Research and Clinical Practice Volume 226, August 2025, 112286
Relation
Has part
Has version
Is based on
Is part of
Is referenced by
Is version of
Requires
Publisher version
https://doi.org/10.1016/j.diabres.2025.112286Sponsors
This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI20/01069 and co-funded by the European Union; and the Network for Research on Chronicity, Primary Care, and Health Promotion, Instituto de Salud Carlos III (ISCIII), RD24/0005/0010, co-funded by the European Union. The Galician Innovation Agency-Competitive Benchmark Groups (GAIN-GRC/IN607A/2021/02/Xunta de Galicia) supported MA-S. This project was funded by the European Union (Programme for Research and Innovation, 2021-2027; Horizon Europe, EIC Pathfinder: 101161509-GLUCOTYPES). OL-B was granted by ISCIII Support Platforms for Clinical Research (PT23/00118/Co-funded by European Union).
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International








